The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications.
The blood-based assay, which uses the company's nucleosome detection technology, is the first of several that will be bundled together as a test for cancer diagnosis.
The study will evaluate the ability of VolitionRx's technology to detect prostate cancer and to distinguish different prostate conditions and healthy samples.
The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells.
The firm, which was previously listed on the over-the-counter market, anticipates $8.5 million in net proceeds from the offering.
SingaporeGeneralHospitalwill provide blood and tissue samples for the pilot study, which is meant to establish the feasibility of VolitionRx's technology.
The study will evaluate VolitionRx's Nucleosomics platform in blood tests, adding to existing studies assessing the firm's technology at the university.
NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with the University of Oxford on a clinical study to develop biomarkers for the diagnosis of endometriosis using the firm's Nucleosomics platform.
NEW YORK (GenomeWeb News) – VolitionRx said today it has reached a deal with Active Motif to co-exclusively distribute VolitionRx's NuQ product line in Europe, the US, and Japan.
NEW YORK (GenomeWeb News) – Cancer diagnostics firm VolitionRx has raised $595,000 toward a targeted $1.5 million round, it said in a document filed with the US Securities and Exchange Commission.
In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.
Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.
Researchers are using gene editing to develop more robust livestock and crops, AFP reports.
Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.